These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 27453265)
1. Synthesis, SAR and biological evaluation of a novel series of 1-(2-chloroethyl)-1-nitroso-3-(2-(3-oxobenzoelenazol-2(3H)-yl)ethyl) urea: Organoselenium compounds for cancer therapy. Ye S; Zheng X; Hu T; Zeng H Cell Mol Biol (Noisy-le-grand); 2016 Jun; 62(7):6-14. PubMed ID: 27453265 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of thioredoxin reductase by a novel series of bis-1,2-benzisoselenazol-3(2H)-ones: Organoselenium compounds for cancer therapy. He J; Li D; Xiong K; Ge Y; Jin H; Zhang G; Hong M; Tian Y; Yin J; Zeng H Bioorg Med Chem; 2012 Jun; 20(12):3816-27. PubMed ID: 22579620 [TBL] [Abstract][Full Text] [Related]
3. Synergism between thioredoxin reductase inhibitor ethaselen and sodium selenite in inhibiting proliferation and inducing death of human non-small cell lung cancer cells. Zheng X; Xu W; Sun R; Yin H; Dong C; Zeng H Chem Biol Interact; 2017 Sep; 275():74-85. PubMed ID: 28757135 [TBL] [Abstract][Full Text] [Related]
4. Ethaselen: a potent mammalian thioredoxin reductase 1 inhibitor and novel organoselenium anticancer agent. Wang L; Yang Z; Fu J; Yin H; Xiong K; Tan Q; Jin H; Li J; Wang T; Tang W; Yin J; Cai G; Liu M; Kehr S; Becker K; Zeng H Free Radic Biol Med; 2012 Mar; 52(5):898-908. PubMed ID: 22210352 [TBL] [Abstract][Full Text] [Related]
5. A novel organoselenium compound induces cell cycle arrest and apoptosis in prostate cancer cell lines. Shi C; Yu L; Yang F; Yan J; Zeng H Biochem Biophys Res Commun; 2003 Sep; 309(3):578-83. PubMed ID: 12963029 [TBL] [Abstract][Full Text] [Related]
6. Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents. Engman L; Cotgreave I; Angulo M; Taylor CW; Paine-Murrieta GD; Powis G Anticancer Res; 1997; 17(6D):4599-605. PubMed ID: 9494575 [TBL] [Abstract][Full Text] [Related]
7. Dose-biomarker-response modeling of the anticancer effect of ethaselen in a human non-small cell lung cancer xenograft mouse model. Ye SF; Li J; Ji SM; Zeng HH; Lu W Acta Pharmacol Sin; 2017 Feb; 38(2):223-232. PubMed ID: 27917873 [TBL] [Abstract][Full Text] [Related]
8. Some new congeners of the anticancer agent 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Synthesis of bifunctional analogs and water soluble derivatives and preliminary evaluation of their chemotherapeutic potential. Eisenbrand G; Fiebig HH; Zeller WJ Z Krebsforsch Klin Onkol Cancer Res Clin Oncol; 1976 Aug; 86(3):279-86. PubMed ID: 136102 [TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of new nitrosoureas on Yoshida sarcoma ascites cells implanted into the colon wall of rats. Habs M; Reinbold H; Eisenbrand G; Bhide S; Goga-Ionescu S; Schmähl D J Cancer Res Clin Oncol; 1981; 101(3):285-302. PubMed ID: 7309781 [TBL] [Abstract][Full Text] [Related]
10. Novel mechanism of ethaselen in poorly differentiated colorectal RKO cell growth inhibition: Simultaneous regulation of TrxR transcription, expression and enzyme activity. Yin H; Li J; Xiong K; Wang L; Wang T; Tan Q; Fu J; Ren X; Zeng H Differentiation; 2011 Jan; 81(1):49-56. PubMed ID: 20864247 [TBL] [Abstract][Full Text] [Related]
11. The inhibitory effect of a novel organoselenium compound BBSKE on the tongue cancer Tca8113 in vitro and in vivo. Xing F; Li S; Ge X; Wang C; Zeng H; Li D; Dong L Oral Oncol; 2008 Oct; 44(10):963-9. PubMed ID: 18282784 [TBL] [Abstract][Full Text] [Related]
12. Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo. Tan Q; Li J; Yin HW; Wang LH; Tang WC; Zhao F; Liu XM; Zeng HH Invest New Drugs; 2010 Jun; 28(3):205-15. PubMed ID: 19271154 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and in vitro antiproliferative evaluation of novel hybrids from 1,3,4-thiadiazole and benzisoselenazolone. Jing F; Fu X; Li S; Li B; Zhao J; Wang X; Liu Y; Chen B Chem Pharm Bull (Tokyo); 2015; 63(6):431-7. PubMed ID: 26027467 [TBL] [Abstract][Full Text] [Related]
14. Thioredoxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrest. Fu JN; Li J; Tan Q; Yin HW; Xiong K; Wang TY; Ren XY; Zeng HH Invest New Drugs; 2011 Aug; 29(4):627-36. PubMed ID: 20195699 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and anticancer effects evaluation of 1-alkyl-3-(6-(2-methoxy-3-sulfonylaminopyridin-5-yl)benzo[d]thiazol-2-yl)urea as anticancer agents with low toxicity. Xie XX; Li H; Wang J; Mao S; Xin MH; Lu SM; Mei QB; Zhang SQ Bioorg Med Chem; 2015 Oct; 23(19):6477-85. PubMed ID: 26321603 [TBL] [Abstract][Full Text] [Related]
16. Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity. Ng HL; Chen S; Chew EH; Chui WK Eur J Med Chem; 2016 Jun; 115():63-74. PubMed ID: 26994844 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and Biological Evaluation of Novel 1,3,4-thiadiazole Derivatives Incorporating Benzisoselenazolone Scaffold as Potential Antitumor Agents. Fu X; Li S; Jing F; Wang X; Li B; Zhao J; Liu Y; Chen B Med Chem; 2016; 12(7):631-639. PubMed ID: 26833076 [TBL] [Abstract][Full Text] [Related]
18. Anticancer activity of new nitrosoureas against Walder carcinosarcoma 256 and DMBA-induced mammary cancer of the rat. Fiebig HH; Eisenbrand G; Zeller WJ; Zentgraf R Oncology; 1980; 37(3):177-83. PubMed ID: 6444708 [TBL] [Abstract][Full Text] [Related]
19. Biological activity of hydroxylated chloroethylnitrosoureas. Zeller WJ; Frühauf S; Chen G; Eisenbrand G; Lijinsky W Cancer Res; 1989 Jun; 49(12):3267-70. PubMed ID: 2720679 [TBL] [Abstract][Full Text] [Related]
20. Selenadiazole derivatives as potent thioredoxin reductase inhibitors that enhance the radiosensitivity of cancer cells. Liang YW; Zheng J; Li X; Zheng W; Chen T Eur J Med Chem; 2014 Sep; 84():335-42. PubMed ID: 25036792 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]